Trial Profile
A Pilot, Open-Label, Single Arm Study to Investigate the Safety and Efficacy of Boceprevir in Combination with Peginterferon/Ribavirin in HCV Genotype 1 (HCV-1)/HBV Dually-Infected Patients Refractory to Prior Peginterferon/Ribavirin
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Nov 2018
Price :
$35
*
At a glance
- Drugs Boceprevir (Primary) ; Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
- Indications Hepatitis B; Hepatitis C
- Focus Therapeutic Use
- Acronyms BOLERO
- 02 Nov 2018 New trial record